Assessment of Serum (1→3)-β- d -Glucan Concentration as a Measure of Disease Burden in a Murine Model of Invasive Pulmonary Aspergillosis-Reference-Cited by-同舟云学术

Assessment of Serum (1→3)-β- d -Glucan Concentration as a Measure of Disease Burden in a Murine Model of Invasive Pulmonary Aspergillosis

Published:2008-03 Issue:3 Volume:52 Page:1176-1178
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Wiederhold Nathan P.¹²,Najvar Laura K.²,Vallor Ana C.²,Kirkpatrick William R.²,Bocanegra Rosie²,Molina Destiny²,Olivo Marcos²,Graybill John R.²,Patterson Thomas F.²

Affiliation:

1. The University of Texas at Austin College of Pharmacy, Austin, Texas

2. The University of Texas Health Science Center at San Antonio, Department of Medicine, Division of Infectious Diseases, San Antonio, Texas

Abstract

ABSTRACT Serum (1→3)-β- d -glucan concentrations were serially measured in the presence and absence of antifungal therapy in a murine model of invasive pulmonary aspergillosis. Serum (1→3)-β- d -glucan was detected early during the course of infection, and reductions in this biomarker were associated with improved survival in animals treated with antifungal agents.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01425-07

Reference9 articles.

1. Alvarez, C. A., N. P. Wiederhold, J. T. McConville, J. I. Peters, L. K. Najvar, J. R. Graybill, J. J. Coalson, R. L. Talbert, D. S. Burgess, R. Bocanegra, K. P. Johnston, and R. O. Williams III. 2007. Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. J. Infect.55:68-74.

2. Caillot, D., O. Casasnovas, A. Bernard, J. F. Couaillier, C. Durand, B. Cuisenier, E. Solary, F. Piard, T. Petrella, A. Bonnin, G. Couillault, M. Dumas, and H. Guy. 1997. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J. Clin. Oncol.15:139-147.

3. Caillot, D., L. Mannone, B. Cuisenier, and J. F. Couaillier. 2001. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. Clin. Microbiol. Infect.7(Suppl. 2):54-61.

4. Maertens, J., K. Theunissen, G. Verhoef, J. Verschakelen, K. Lagrou, E. Verbeken, A. Wilmer, J. Verhaegen, M. Boogaerts, and J. Van Eldere. 2005. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin. Infect. Dis.41:1242-1250.

5. Marr, K. A., M. Laverdiere, A. Gugel, and W. Leisenring. 2005. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin. Infect. Dis.40:1762-1769.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Antifungal Pharmacodynamics;Journal of Fungi;2023-02-01

2. Modeling Invasive Aspergillosis: How Close Are Predicted Antifungal Targets?;Journal of Fungi;2020-09-30

3. Prognostic Potential of the Panfungal Marker (1 → 3)-β-d-Glucan in Invasive Mycoses Patients;Mycopathologia;2018-07-02

4. Central Role of IL-23 and IL-17 Producing Eosinophils as Immunomodulatory Effector Cells in Acute Pulmonary Aspergillosis and Allergic Asthma;PLOS Pathogens;2017-01-17

5. Effects of host response and antifungal therapy on serum and BAL levels of galactomannan and (1→3)-β-D-glucan in experimental invasive pulmonary aspergillosis;Medical Mycology;2015-06-30